Literature DB >> 21835195

Liver cirrhosis as a risk factor for mortality in a national cohort of patients with bacteremia.

Cheol-In Kang1, Jae-Hoon Song, Doo Ryeon Chung, Kyong Ran Peck, Joon-Sup Yeom, Hyun Kyun Ki, Jun Seong Son, Jin Seo Lee, Yeon-Sook Kim, Sook-In Jung, Shin-Woo Kim, Hyun-Ha Chang, Seong Yeol Ryu, Ki Tae Kwon, Hyuck Lee, Dong Sik Jung, Chisook Moon, Sang Taek Heo, Eu Suk Kim, Ji-Young Rhee.   

Abstract

OBJECTIVE: The purpose of this study was to evaluate clinical features and outcomes of bacteremia in patients with liver cirrhosis (LC) and determine whether underlying LC is an independent risk factor for mortality in a population of patients with different underlying diseases.
METHODS: From the database of nationwide surveillance studies for bacteremia, data regarding bacteremia in patients with LC were analyzed and compared with those in patients with other diseases.
RESULTS: A total of 195 patients with LC were compared with 1659 patients with other underlying diseases. As for the site of infection, intraabdominal infection was more frequent in the LC group (P < 0.001), while pneumonia, urinary tract bacteremia, and primary bacteremia were more prevalent in the other diseases group (all P < 0.05). Patients with LC were more likely to have Klebsiella pneumoniae bacteremia (20.1% vs. 14.3%, P = 0.018), but less likely to have coagulase-negative staphylococcal bacteremia (5.1% vs. 10.4%, P = 0.028). The 30-day mortality rate was significantly higher in the LC group compared to the other disease group (27.2% [53/195] vs. 20.3% [336/1659], P = 0.025). Multivariate analysis revealed underlying LC as a significant predictor for mortality (OR, 2.11; 95% CI, 1.43-3.13; P < 0.001), along with old age, nosocomial acquisition, pneumonia, severe sepsis, and a higher Pitt bacteremia score.
CONCLUSIONS: The mortality rate of patients with LC was significantly higher than that of patients with other diseases when they developed bacteremia. Underlying LC was found to be one of the independent risk factors for mortality in patients with bacteremia.
Copyright © 2011 The British Infection Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21835195     DOI: 10.1016/j.jinf.2011.07.012

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  16 in total

Review 1.  Bacterial infections in end-stage liver disease: current challenges and future directions.

Authors:  Jasmohan S Bajaj; Jacqueline G O'Leary; Florence Wong; K Rajender Reddy; Patrick S Kamath
Journal:  Gut       Date:  2012-06-03       Impact factor: 23.059

2.  Appropriate empirical antibiotic use and 30-d mortality in cirrhotic patients with bacteremia.

Authors:  Hyun Park; Ki Jun Jang; Won Jang; Sang Hoon Park; Ji Young Park; Tae Joo Jeon; Tae Hoon Oh; Won Chang Shin; Won-Choong Choi; Dong Hyun Sinn
Journal:  World J Gastroenterol       Date:  2015-03-28       Impact factor: 5.742

3.  Epidemiological characteristics of bloodstream infections in patients with different degrees of liver disease.

Authors:  Micaela Brandolini; Marta Corbella; Annalisa De Silvestri; Carmine Tinelli; Giulia Albonico; Riccardo Albertini; Serena Ludovisi; Raffaele Bruno; Piero Marone; Lorenzo Minoli; Elena Seminari
Journal:  Infection       Date:  2015-05-15       Impact factor: 3.553

Review 4.  Abnormalities of Lipoprotein Levels in Liver Cirrhosis: Clinical Relevance.

Authors:  Graziella Privitera; Luisa Spadaro; Simona Marchisello; Giuseppe Fede; Francesco Purrello
Journal:  Dig Dis Sci       Date:  2017-11-25       Impact factor: 3.199

5.  Long-term influence of chemotherapy on steatosis-associated advanced hepatic fibrosis.

Authors:  Srinevas K Reddy; Colleen Reilly; Min Zhan; Ayse L Mindikoglu; Yixing Jiang; Barton F Lane; H Richard Alexander; William J Culpepper; Samer S El-Kamary
Journal:  Med Oncol       Date:  2014-05-06       Impact factor: 3.064

6.  Infective endocarditis in patients with hepatic diseases.

Authors:  E Seminari; A De Silvestri; V Ravasio; S Ludovisi; R Utili; N Petrosillo; F Castelli; M Bassetti; F Barbaro; P Grossi; N Barzaghi; M Rizzi; L Minoli
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-12-21       Impact factor: 3.267

7.  External validation of bloodstream infection mortality risk score in a population-based cohort.

Authors:  M N Al-Hasan; Y J Juhn; D W Bang; H-J Yang; L M Baddour
Journal:  Clin Microbiol Infect       Date:  2014-03-26       Impact factor: 8.067

Review 8.  Bloodstream infections in patients with liver cirrhosis.

Authors:  Michele Bartoletti; Maddalena Giannella; Russell Edward Lewis; Pierluigi Viale
Journal:  Virulence       Date:  2016-02-11       Impact factor: 5.882

9.  Group B streptococcal bacteremia in non-pregnant adults: results from two Korean centers.

Authors:  S Y Park; Y Park; J-W Chung; H J Huh; S L Chae; Y A Kim; S S Lee
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-05-14       Impact factor: 3.267

10.  Investigation of Bacteremia due to Aeromonas Species and Comparison with That due to Enterobacteria in Patients with Liver Cirrhosis.

Authors:  Toru Shizuma; Chiharu Tanaka; Hidezo Mori; Naoto Fukuyama
Journal:  Gastroenterol Res Pract       Date:  2011-12-29       Impact factor: 2.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.